Novavax still plans to push RSV vaccine to market after failed trial

It’s official: Novavax Inc. will have to complete another clinical trial for its respiratory syncytial virus vaccine candidate for infants, ResVax, lengthening its road to market by roughly three years following its failed phase 3 trial in March.